ClinicalTrials.gg
RecruitingNCT05646511ENSEMBLEUpdated Apr 3, 2025

TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer

A Phase 3 interventional study of SCRT and CAPOX in Locally Advanced Rectal Cancer, sponsored by National Cancer Center Hospital East. Recruiting at 34 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by National Cancer Center Hospital East · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
608
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Rectal Neoplasms with a site in Japan — 7 open to participants now, 12 under way, 5 of them phase 3. Rectal Neoplasms · Japan.

Planned enrollment
5th of 24
608 · median 105
Started
2022
with 1 other
Phase 3
8 of 26
4 open now
Primary completion
2029-12
later than 9 of 11 live
Registered
18th of 26
by date
Lead sponsor
2 of 26
National Cancer Center Hospital East

Among the 26 studies in Rectal Neoplasms with a site in Japan, this one is the 5th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2022, is one of 8 in phase 3, reaches primary completion later than 9 of the 11 other live ones, and was the 18th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

7 of the 26 studies in Rectal Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Rectal Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

This trial is a multicenter randomized Phase III study to verify the superiority of short-course preoperative radiation (SCRT) and CAPOXIRI over SCRT and CAPOX as preoperative treatments for locally advanced rectal cancer.

Read the detailed description

Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) has the promise, which means non-operative management (NOM) enable more patients (pts) with a complete clinical response (cCR) or near-complete clinical responses (nCR) after TNT to avoid subsequent radical surgery, with potentially maintaining anorectal function and quality of life (QoL). Recently, PRODIGE-23 trial demonstrated that triplet regimen (Irinotecan, oxaliplatin and fluoropyrimidine) before preoperative chemoradiotherapy (CRT) significantly improved outcomes compared with CRT. However, there has been no prospective study comparing consolidation triplet with doublet regimens following short course radiotherapy (SCRT). The aim of this randomized phase III trial is to test superiority of consolidation irinotecan, capecitabine and oxaliplatin (CAPOXIRI) vs. capecitabine and oxaliplatin (CAPOX) following SCRT as TNT in pts with LARC.

Pts in both groups will be re-staged after completing TNT before radical surgery according to the Memorial Sloan Kettering Regression Schema; pts with incomplete response (iCR) will undergo total mesorectal excision (TME), cCR pts will receive NOM, and nCR pts will undergo TME or NOM by a physician discretion under the recommendation of blind assessment by the designated NOM central committee. Pts will be followed by CT, MRI, colonoscopy and liquid biopsy every 4 months for 2 years, and every 6 months thereafter up to 5 years.

To detect a decrease in 3-year cumulative probability of organ preservation-adapted Disease free survival (DFS) from 75.0% to 81.7%, corresponding to a target hazard ratio of 0·70, a total of 608 pts (196 events) would achieve 70% power at a two-sided α significance level of 0.05.

03

Conditions studied

  • Locally Advanced Rectal Cancer

Keywords

  • Radiation
  • CAPOXIRI
  • CAPOX
  • Rectal cancer
  • Total neoadjuvant therapy
  • Rectal Neoplasms
  • Colorectal Neoplasms
  • Intestinal Neoplasms
  • Gastrointestinal Neoplasms
  • Digestive System Neoplasms
  • Capecitabine
  • Oxaliplatin
  • Irinotecan
  • Antineoplastic Agents
  • Chemotherapy
  • Non-operative management
  • Surgery
  • MRI
  • Restaging
  • QOL
  • Organ preservation
  • TNT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The content of this research was fully explained, and written was obtained from the subject.
  2. confirmed rectal adenocarcinoma.
  3. Radical resection is clinically possible without any distant on imaging studies.
  4. Age of 18 years or older on the date of consent acquisition.
  5. (ECOG) PS 0-1 (PS 0 if aged 70 years or older on consent acquisition date).
  6. Inferior margin of the tumor is within 12 cm of the AV.
  7. No prior tumor treatment.
  8. No history of radiation therapy to the pelvis, including treatment for other cancer types.
  9. Cases with cT3-4N0M0*or T1-4N1-2M0 based on Union Internationale Contre le Cancer (UICC) 8th edition.

    (*5 cm\< AV ≤ 10 cm, T3a/bN0M0, extramural venous invasion (EMVI) -, mesorectal fascia (MRF) clear and 10 cm \< AV ≤ 12 cm, T3a/bN0-1M0, EMVI-, MRF clear are eligible only for those who refused surgery)

  10. UGT1A1 is wild-type or single heterozygous.
  11. Criteria for major organ function within 28 days prior to enrollment. If there are multiple test results within this period, the most recent one will be used, and blood transfusions and hematopoietic factor preparations will not be administered within 14 days before the test date for measurements before registration.

    1. : ≥1,500/mm3
    2. count: ≥10.0×10 4/mm3
    3. concentration: ≥9.0 g/dL
    4. Total : ≤2.0 mg/dL
    5. (AST): ≤100 IU/L or less
    6. Alanine transaminase (ALT): ≤100 IU/L or less
    7. Serum creatinine: ≥30 mL/min (by Cockcroft \& Gault formula)

Exclusion criteria

Exclusion Criteria:

  1. Extensive surgery (excluding colostomy and central venous port construction) within 4 weeks before starting protocol treatment.
  2. Complications or history of severe lung disease (such as interstitial pneumonia, pulmonary fibrosis, and severe emphysema).
  3. Colonic stent in place.
  4. for MRI such as cardiac pacemakers.
  5. Serious comorbidities (such as heart failure, renal failure, liver failure, intestinal paralysis, intestinal obstruction, uncontrolled diabetes, and active inflammatory bowel disease).
  6. Patients with multiple active cancers (simultaneous multiple cancers or metachronous multiple cancers with a disease-free interval of 5 years or less). However, carcinoma in situ or lesions equivalent to intramucosal carcinoma, which can be cured by local treatment, are not treated as active multiple cancers.
  7. Pregnant women, lactating women, positive pregnancy test, or unwillingness to use .
  8. surface (HBs) antigen positive or virus (HCV) antibody-positive. However, HCV-RNA-negative can be registered.
  9. Have (HIV) infection.
  10. MSI-high (MSI-H) or defective mismatch repair (dMMR) is known.
  11. Unwilling to donate specimens for "Research on gene profiling and clinical significance using clinical specimens from cancer patients" for whole-genome analysis based on the "Action Plan for Whole-Genome Analysis, etc." (CONDUCTOR study).
  12. Any other patients the principal investigator or co-investigator deems inappropriate for study participation.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
608 participants (estimated)

Study arms

  • Active comparator
    Control arm SCRT+CAPOX

    The standard-of-care group receives short-course radiation therapy (5 × 5 Gy) followed by six cycles of CAPOX (capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, q3wks).

    Radiation: SCRT · Drug: CAPOX

  • Experimental
    Experimental arm SCRT+CAPOXIRI

    The standard-of-care group receives short-course radiation therapy (5 × 5 Gy) followed by six cycles of CAPOXIRI (capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, and irinotecan 150 mg/m2 intravenously on day 1\*, q3wks).

    Radiation: SCRT · Drug: CAPOXIRI

Interventions

  • RadiationSCRT

    5x5 Gy: 25 Gy

    Also known as: Active Comparator & Experimental

  • DrugCAPOX

    Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks

    Also known as: Active Comparator

  • DrugCAPOXIRI

    Six cycles of CAPOXIRI capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 150 mg/m2 intravenously on day 1, every 3 weeks

    Also known as: Experimental

06

What researchers measure

Primary outcomes

  1. Organ-preservation adapted DFS

    The investigators use the definition of organ-preservation adopted DFS proposed in the international consensus statement for preoperative treatment (75). It is defined as the period from the date of allocation to the earliest of the following events. 1. Surgery difficult due to local progression or study subject unfit for surgery 2. R2 resection of primary tumor ( not including Circumferential resection margin (CRM) positive ) 3. Local recurrence after R0/1 resection of primary tumor 4. Local regrowth for which Salvage surgery is not possible during NOM 5. Appearance of distant metastases 6. Occurrence of second primary colorectal cancer 7. Development of second primary other cancers 8. Death (treatment-related death, death from the same cancer, death from a different type of cancer, non-cancer-related death)

    Time frame: Up to 3 years. It is defined as the period from the allocation date to the earliest of the following events.

Secondary outcomes

  1. cCR rate

    The investigators will use the Memorial Sloan Kettering Regression Schema, which is the cCR standard for TNT clinical trials conducted mainly in the United States. For judgment, a gastrointestinal endoscopist, a pathological diagnostician, and a gastrointestinal surgeon discuss and comprehensively judge.

    Time frame: 1-3 weeks (Days 7-21) from the completion of preoperative chemotherapy or the date of discontinuation.

  2. Clinical response (cCR+near CR [nCR]) rate

    The investigators will use the Memorial Sloan Kettering Regression Schema, which is the cCR standard for TNT clinical trials conducted mainly in the United States. For judgment, a gastrointestinal endoscopist, a pathological diagnostician, and a gastrointestinal surgeon discuss and comprehensively judge.

    Time frame: Within 1-3 weeks (Days 7-21) from the completion of preoperative chemotherapy or the date of discontinuation.

  3. Proportion of NOM selection

    The proportion of the number of research subjects for whom NOM was selected at the time of re-evaluation to the analysis population as the numerator. Study subjects who died of any cause before the re-evaluation decision date will be treated as "no complete resection" and included in the denominator but not the numerator.

    Time frame: 3-6 weeks (Days 21-42) from the completion of preoperative chemotherapy or the date of discontinuation.

  4. Recurrence type and recurrence rate

    The recurrence site is classified into local recurrence, distant recurrence, and unknown, and is defined as "recurrence type". Select multiple categories if recurrence is observed at multiple sites at the time of the first recurrence.

    Time frame: 3 years (up to 5 years)

  5. Distant metastases free survival (DMFS)

    The period from the date of allocation to the date of determination of distant metastasis or the date of death due to any cause, whichever is earlier. An event that corresponds to any of the following is defined as a DMFS event. 1. Distant metastasis 2. Death (treatment-related death, death from the same cancer, death from a different type of cancer, non-cancer-related death)

    Time frame: 3 years (up to 5 years)

  6. Local recurrence-free survival (LRFS)

    The period from the date of allocation to the date of local recurrence or the date of death due to any cause, whichever is earlier. An event that corresponds to any of the following is defined as an LRFS event. 1. Local recurrence 2. Death (treatment-related death, death from the same cancer, death from a different type of cancer, non-cancer-related death)

    Time frame: 3 years (up to 5 years)

  7. Overall survival (OS)

    From the date of allocation to the date of death due to any cause. Based on " Protocol 8.2.17 Confirmation of outcome and confirmation of recurrence after protocol treatment", the confirmation of survival should be recorded in the medical record, etc.). Patients with no follow-up will be censored on the date of final confirmation of survival.

    Time frame: 3 years (up to 5 years)

  8. TME-free survival

    As the earliest of the date of definitive TME at reevaluation, the date of TME at local recurrence (excluding local excision), and the date of death from any cause. An event corresponding to any of the following is defined as a TME free survival event. 1. TME when electing surgery at reevaluation 2. TME with salvageable local regrowth in NOM 3. Death (treatment-related death, death from the same cancer, death from a different type of cancer, non-cancer-related death)

    Time frame: 3 years (up to 5 years)

  9. TME-free DFS

    With the date of assignment as the starting date, the date on which radical TME was performed at reevaluation, the date on which TME was performed at the time of local recurrence (excluding local excision), and Organ-preservation adopted DFS defined in Protocol 12.2.1. The period up to the earliest of the event occurrence dates. An event that corresponds to any of the following is defined as an event of TME-free disease-free survival. 1. TME when electing surgery at reevaluation 2. TME with salvageable local regrowth in NOM 3. Organ preservation - adopted DFS defined in Protocol 12.2.1. is not applicable because TME is implemented)

    Time frame: 3 years (up to 5 years)

  10. Protocol treatment completion rate

    The analysis population who completed protocol treatment.

    Time frame: Immediately after the completion of preoperative chemotherapy or the date of discontinuation.

  11. Relative dose intensity (RDI)

    RDI is calculated for each case, each cycle, and each drug (capecitabine, oxaliplatin, irinotecan) in the analysis target population. The actual number of cycle days refers to the number of days from the start of the corresponding course to the start date of the next course, but the actual number of cycle days in the final course is the number of days from the start date of the last course to the actual day of administration of capecitabine + 6 days. defined as RDI (%) = (Actual Dose/Prescribed Dose) x (21/Actual Cycle Days) x 100

    Time frame: Immediately after the completion of preoperative chemotherapy or the date of discontinuation.

  12. QOL assessment (LARS score, EORTC QLQ-C30, and SF-36)

    Using a quality of life questionnaire to assess the following items: LARS score, EORTC QLQ-C30, SF-36

    Time frame: 3 years

  13. Incidence of preoperative treatment-related adverse events

    Incidence of preoperative treatment-related adverse events determined by CTCAE ver5.0

    Time frame: Immediately after the completion of preoperative chemotherapy or the date of discontinuation.

  14. Pathological complete response (pCR) rate in the surgical subgroup

    Pathological response evaluation will be performed on the surgical specimens of the subgroup that underwent surgical resection in the protocol treatment. Histopathological evaluation of antitumor efficacy is based on the American Joint Committee on Cancer (AJCC) evaluation method. pCR is defined as no viable tumor cells not only in the primary tumor but also in the regional lymph nodes (ypT0N0). Percentage of study subjects judged to be pCR in the analysis population.

    Time frame: Immediately after the evaluation of the histopathological findings after surgery

  15. Radical resection rate in the surgical subgroup

    Proportion of study participants who underwent a complete resection (confirmed postoperative pathological R0) in the analyzed population in the surgical resection subgroup in protocol treatment. Study subjects who died of any cause prior to the date of surgery were treated as "no complete resection" and included in the denominator but not the numerator.

    Time frame: 3 years (up to 5 years)

  16. Local recurrence-free survival (LRFS) in the surgical subgroup

    In the subgroup that underwent surgical resection in protocol treatment, the period from the date of surgery to the date of local recurrence or the date of death from any cause, whichever comes first.

    Time frame: 3 years (up to 5 years)

  17. Surgery-related adverse event rate determined by Clavien-Dindo classification v2.0 in the surgical subgroup

    For early (within 30 days) and late (31-90 days) postoperative adverse events after the end of surgical therapy, the worst grade according to the Clavien-Dindo classification v2.0 is calculated.

    Time frame: For early (within 30 days) and late (31-90 days) postoperative adverse events after the end of surgical therapy

  18. Local re-enlargement rate in the NOM subgroup

    Proportion of study subjects with local regrowth in the analysis population in the subgroups that underwent NOM.

    Time frame: 3 years (up to 5 years)

  19. Time for local regrowth in the NOM subgroup

    In the subgroup that underwent NOM, the date of NOM determination is the starting date, and the period from the date of local regrowth to the date of death from any cause, whichever is earlier.

    Time frame: 3 years (up to 5 years)

  20. Proportion of salvage surgery in local re-enlargement cases in the NOM subgroup

    In the NOM subgroup, the proportion of study subjects with local regrowth and salvage surgery in the analysis population.

    Time frame: 3 years (up to 5 years)

  21. Time until salvage surgery in the NOM subgroup

    In the NOM subgroup, the time to the date of salvage surgery at the time of local regrowth or the date of death from any cause, whichever is earliest.

    Time frame: 3 years (up to 5 years)

  22. Surgery-related adverse event rate determined by Clavien-Dindo classification v2.0 in salvage surgery cases in the NOM subgroup

    In the subgroup that underwent NOM, among the population to be analyzed, in cases where local regrowth was performed and salvage surgery was performed, early (within 30 days) and late (31-90 days) postoperative adverse events after the end of surgical therapy , find the worst grade by Clavien-Dindo classification v2.0.

    Time frame: For early (within 30 days) and late (31-90 days) postoperative adverse events after the end of surgical therapy

  23. Proportion of radical resection in salvage surgery cases in the NOM subgroup

    Proportion of study subjects with local regrowth and radical salvage surgery in the analyzed population in the NOM subgroup.

    Time frame: 3 years (up to 5 years)

Other outcomes

  1. liquid biopsy

    Analysis using liquid biopsy will be performed to identify biomarkers that predict therapeutic effects by performing blood genome profiling.

    Time frame: 3 years (up to 5 years)

  2. Artificial Intelligence (AI) (deep learning) analysis

    Using multiple algorithms, in addition to colonoscopy and pelvic MRI images at each point, clinicopathological features, various biomarkers, and QOL will be utilized to estimate the optimal treatment method for individual research subjects

    Time frame: 3 years (up to 5 years)

07

Study locations

34 of 34 sites recruiting
  • National Cancer Center Hospital East
    Chiba, Japan
    Recruiting
    • Takayuki Yoshino, Dr. · Contact+81-4-7133-1111
  • Ehime Prefectural Central Hospital
    Ehime, Japan
    Recruiting
    • Masanori Hotchi, Dr. · Contact+81-89-947-1111
  • Kyushu University Hospital
    Fukuoka, Japan
    Recruiting
    • Eiji Oki, Dr. · Contact+81-92-641-1151
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, Japan
    Recruiting
    • Masahiko Sugiyama, Dr. · Contact+81-92-557-6100
  • National Hospital Organization Kyushu Medical Center
    Fukuoka, Japan
    Recruiting
    • Tetsuya Kusumoto, Dr. · Contact+81-92-852-0700
  • Gifu University Hospital
    Gifu, Japan
    Recruiting
    • Nobuhisa Matsuhashi, Dr. · Contact+81-58-230-6000
  • Hirosaki University Hospital
    Hirosaki, Japan
    Recruiting
    • Takuya Miura, Dr. · Contact+81-172-33-5111
  • Hiroshima University Hospital
    Hiroshima, Japan
    Recruiting
    • Hideki Ohdan, Dr. · Contact+81-82-257-5555
  • St. Marianna University Hospital
    Kawasaki, Japan
    Recruiting
    • Naoki Izawa, Dr. · Contact+81-44-977-8111
  • University of Occupational and Environmental Health Hospital
    Kitakyushu, Japan
    Recruiting
    • Keiji Hirata, Dr. · Contact+81-93-603-1611
  • Kochi Medical School Hospital
    Kochi, Japan
    Recruiting
    • Hironaga Satake, Dr. · Contact+81-88-866-5811
  • Kumamoto University Hospital
    Kumamoto, Japan
    Recruiting
    • Yuji Miyamoto, Dr. · Contact+81-96-373-5212
  • Kyoto Prefectural University of Medicine
    Kyoto, Japan
    Recruiting
  • Nagoya University Hospital
    Nagoya, Japan
    Recruiting
    • Goro Nakayama, Dr. · Contact+81-52-741-2111
  • Ohara Memorial Kurashiki Central Medical Organization Kurashiki Central Hospital
    Okayama, Japan
    Recruiting
    • Mitsuru Yokota, Dr. · Contact+81-86-422-0210
  • Okayama University Hospital
    Okayama, Japan
    Recruiting
    • Toshiyoshi Fujiwara, Dr. · Contact+81-86-223-7151
  • Kansai Medical University Hospital
    Osaka, Japan
    Recruiting
    • Jun Watanabe, Dr. · Contact+81-72-804-0101
  • Kindai University Hospital
    Osaka, Japan
    Recruiting
    • Junichiro Kawamura, Dr. · Contact+81-72-366-0221
  • National Hospital Organization Osaka Medical Center
    Osaka, Japan
    Recruiting
    • Takeshi Kato, Dr. · Contact+81-6-6942-1331
  • Osaka International Cancer Institute
    Osaka, Japan
    Recruiting
    • Yoshinori Kagawa, Dr. · Contact+81-6-6945-1181
  • Osaka Metropolitan University Hospital
    Osaka, Japan
    Recruiting
  • Osaka Prefectural Hospital Organization Osaka Acute and General Medical Center
    Osaka, Japan
    Recruiting
    • Yujiro Nishizawa, Dr. · Contact+81-6-6692-1201
  • Osaka University Hospital
    Osaka, Japan
    Recruiting
    • Mamoru Uemura, Dr. · Contact+81-6-6879-5111
  • Kitasato University Hospital
    Sagamihara, Japan
    Recruiting
    • Takeshi Naito, Dr. · Contact+81-42-778-8111
  • Sapporo Medical University Hospital
    Sapporo, Japan
    Recruiting
    • Koichi Okuya, Dr. · Contact+81-11-611-2111
  • Keio University Hospital
    Tokyo, Japan
    Recruiting
    • Koji Okabayashi, Dr. · Contact+81-3-3353-1211
  • National Cancer Center Hospital
    Tokyo, Japan
    Recruiting
    • Yukihide Kanemitsu, Dr. · Contact+81-3-3542-2511
  • Nippon Medical School Hospital
    Tokyo, Japan
    Recruiting
    • Takeshi Yamada, Dr. · Contact+81-3-3822-2131
  • Tokyo Medical University Hospital
    Tokyo, Japan
    Recruiting
    • Yuichi Nagakawa, Dr. · Contact+81-3-3342-6111
  • Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Komagome Hospital
    Tokyo, Japan
    Recruiting
    • Kazushige Kawai, Dr. · Contact+81-3-3823-2101
  • Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
    Yokohama, Japan
    Recruiting
    • Manabu Shiozawa, Dr. · Contact+81-45-520-2222
  • Yokohama City University Hospital
    Yokohama, Japan
    Recruiting
    • Mayumi Ozawa, Dr. · Contact+81-45-787-2800
  • Yokohama City University Medical Center
    Yokohama, Japan
    Recruiting
    • Yusuke Suwa, Dr. · Contact+81-45-261-5656
  • Federation of National Public Service Personnel Mutual Aid Associations Yokosuka Mutual Aid Hospital
    Yokosuka, Japan
    Recruiting
    • Hirokazu Suwa, Dr. · Contact+81-46-822-2710
08

References and documents

Publications

  • Watanabe J, Kagawa Y, Chida K, Ando K, Kotani D, Oba K, Bando H, Hojo H, Shimamoto S, Sakashita S et al: Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial. ESMO Gastrointestinal Oncology 2023, 1:9-14.
  • Kagawa Y, Smith JJ, Fokas E, Watanabe J, Cercek A, Greten FR, Bando H, Shi Q, Garcia-Aguilar J, Romesser PB, Horvat N, Sanoff H, Hall W, Kato T, Rodel C, Dasari A, Yoshino T. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nat Rev Gastroenterol Hepatol. 2024 Jun;21(6):444-455. doi: 10.1038/s41575-024-00900-9. Epub 2024 Mar 14. PubMed 38485756 ↗
  • Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, Cusnir M, Dorth J, George M, Kachnic LA, Kennecke HF, Loree JM, Morris VK, Perez RO, Smith JJ, Strickland MR, Gholami S. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol. 2024 Oct;42(28):3355-3375. doi: 10.1200/JCO.24.01160. Epub 2024 Aug 8. PubMed 39116386 ↗
  • Kagawa Y, Watanabe J, Uemura M, Ando K, Inoue A, Oba K, Takemasa I, Oki E. Short-term outcomes of a prospective multicenter phase II trial of total neoadjuvant therapy for locally advanced rectal cancer in Japan (ENSEMBLE-1). Ann Gastroenterol Surg. 2023 Jul 11;7(6):968-976. doi: 10.1002/ags3.12715. eCollection 2023 Nov. PubMed 37927927 ↗
  • Kagawa Y, Ando K, Uemura M, Watanabe J, Oba K, Emi Y, Matsuhashi N, Izawa N, Muto O, Kinjo T, Takemasa I, Oki E. Phase II study of long-course chemoradiotherapy followed by consolidation chemotherapy as total neoadjuvant therapy in locally advanced rectal cancer in Japan: ENSEMBLE-2. Ann Gastroenterol Surg. 2024 Aug 3;8(6):1067-1075. doi: 10.1002/ags3.12848. eCollection 2024 Nov. PubMed 39502728 ↗

Individual participant data

Plan to share: Yes — A part of the omics analysis data obtained in the analysis of this study may be disclosed through public databases such as the "Human Database" operated by National Bioscience Database Center (NBDC) in Japan Science and Technology Agency (JST). When registering data, re-anonymization will be provided to strengthen the protections of personal information. At the time of NBDC registration, we will comply with the "NBDC Guidelines for Human Data Sharing" and "NBDC Security Guidelines for Human Data(for Data Providers)" .

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2029, 85 months after the start.

Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 85 months is above that.

Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 12, 2022
StartActual
Nov 21, 2022
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05646511
Lead sponsor
National Cancer Center Hospital East
Collaborators
Japan Agency for Medical Research and Development
Responsible party
Takayuki Yoshino (MD., PhD Head of Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East) — Principal investigator
First posted
Dec 12, 2022
Start date
Nov 21, 2022
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Apr 3, 2025

Study contacts

Yoshinori Kagawa, MD., PhD
Contact
yoshinori.kagawa@oici.jp
+81-6-6945-1181
Jun Watanabe, MD., PhD
Contact
watanabj@hirakata.kmu.ac.jp
+81-72-804-0101

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion